How long to treat acute venous thrombosis in cancer: Can treatment be personalized?

Journal of Clinical Oncology

Volumn 32, Issue 32, 2014, Pages 3586-3587

  Rana, Punam ^a   Levine, Mark N ^a  

^a Escarpment Cancer Research Institute   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTICOAGULANT AGENT; LOW MOLECULAR WEIGHT HEPARIN;

ANTICOAGULANT THERAPY; BLEEDING; CANCER HORMONE THERAPY; CANCER PATIENT; CANCER PROGNOSIS; DEEP VEIN THROMBOSIS; DISEASE COURSE; EDITORIAL; ESTROGEN RECEPTOR POSITIVE BREAST CANCER; FOLLOW UP; HUMAN; IDIOPATHIC DISEASE; IMPEDANCE PLETHYSMOGRAPHY; LONG TERM CARE; LUNG EMBOLISM; MALIGNANT NEOPLASTIC DISEASE; NEOPLASM; PHYSICIAN; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; TREATMENT DURATION; TREATMENT OUTCOME; VEIN BLOOD FLOW; VENOUS THROMBOEMBOLISM; CARCINOMA, NON-SMALL-CELL LUNG; COMPLICATION; FEMALE; LUNG NEOPLASMS; MALE; VENOUS THROMBOSIS;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASMS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 84911466871     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.6977     Document Type: Editorial

References (10)

1. Lee AY, Levine MN, Baker RI, et al: Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med 349:146-153, 2003
2. Prandoni P, Lensing AW, Piccioli A, et al: Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 100:3484-3488, 2002
3. Lyman GH, Khorana AA, Falanga A, et al: American Society of Clinical Oncology guideline: Recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 25:5490-5505, 2007
4. Prandoni P, Lensing AW, Prins MH, et al: Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 137:955-960, 2002
5. Siragusa S, Malato A, Anastasio R, et al: Residual vein thrombosis to establish duration of anticoagulation after a first episode of deep vein thrombosis: The Duration of Anticoagulation based on Compression UltraSonography (DA-CUS) study. Blood 112:511-515, 2008
6. 5a. Kearon C, Akl EA, Comerota AJ, et al: Antithrombotic therapy for VTE disease: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed-American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141:e419S-e494S 2012 (suppl 2)
7. Levine MN, Hirsh J, Gent M, et al: Optimal duration of oral anticoagulant therapy: A randomized trial comparing four weeks with three months of warfarin in patients with proximal deep vein thrombosis. Thromb Haemost 74:606-611, 1995
8. Lo SS, Mumby PB, Norton J, et al: Prospective multicenter study of the impact of the 21-gene recurrence score assay on medical oncologist and patient adjuvant breast cancer treatment selection. J Clin Oncol 1671-1676, 2010
9. Palareti G, Cosmi B, Legnani C, et al: D-Dimer testing to determine the duration of anticoagulation therapy. N Engl J Med 355:1780-1789, 2006
10. Zwicker JI, Trenor CC 3rd, Furie BC: Tissue factor-bearing microparticles and thrombus formation. Arterioscler Thromb Vasc Biol 31:728-733, 2011